Combined treatment: Antifungal drugs with antibodies, cytokines or drugs

Medical Mycology

Volumn 38, Issue , 2000, Pages 305-315

  Stevens, D A ^a   Kullberg, B J ^b   Brummer, E ^a   Casadevall, A ^c   Netea, M G ^b   Sugar, A M ^d  

^a SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c YESHIVA UNIVERSITY   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antifungal drugs; Combination chemotherapy; Immunomodulation

Indexed keywords

ANTIFUNGAL AGENT; MONOCLONAL ANTIBODY; RECOMBINANT CYTOKINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VORICONAZOLE;

ANIMAL CELL; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; CANDIDIASIS; CLEARANCE; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG POTENTIATION; GENE DELETION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHAGOCYTE; SURVIVAL;

ANIMALS; ANTIBODIES, FUNGAL; ANTIFUNGAL AGENTS; COMBINED MODALITY THERAPY; CYTOKINES; DRUG THERAPY, COMBINATION; HUMANS; MICE; MITOSPORIC FUNGI; MYCOSES;

ANIMALIA;

EID: 0034506748     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/mmy.38.s1.305.315     Document Type: Article

References (92)

1. Different components in human serum inhibit multiplication of Cryptococcus neoformans and enhance fluconazole activity
2. Isolation of a human serum protein that inhibits the growth of Cryptococcus neoformans
3. Characterization of an anticryptococcal protein isolated from human serum
4. Macrophage colony-stimulating factor (M-CSF) induction of enhanced anticryptococcal activity in human monocyte-derived macrophages: Synergy with fluconazole for killing
5. Effect of iron on fluconazole activity against Candida albicans in presence of human serum or monocyte-derived macrophages
6. Synergy of human neutrophils with fluconazole in killing Candida albicans species
7. Effect of granulocyte colony-stimulating factor on the candidacidal activity of polymorphonuclear neutrophils and their collaboration with fluconazole
8. Effect of granulocyte-macrophage colony-stimulating factor on candidacidal activity of neutrophils, monocytes or monocyte-derived macrophages and synergy with fluconazole
9. Activity of voriconazole, a new triazole, combined with neutrophils or monocytes against Candida albicans: Effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor
10. Activity of voriconazole combined with neutrophils or monocytes against Aspergillus fumigatus: Effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor
11. Persistence of the initial infection in recurrent cryptococcal meningitis
12. Prognostic factors in cryptococcal meningitis
13. Opsonization of Cryptococcus neoformans by human anticryptococcal glucuronoxylomannan antibodies
14. Phagocytosis of Cryptococcus neoformans by serum from recipients of cryptococcal polysaccharide vaccine
15. Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV- individuals
16. Cryptococcus neoformans antibody levels in patients with AIDS
17. Torula meningitis
18. Cryptococcosis (Torulosis)
19. Serum therapy of cryptococcal meningitis
20. Improved amphotericin B activity by a monoclonal anti-Cryptococcus neoformans antibody: Study during murine cryptococcosis and mechanisms of action
21. Production, characterization, and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neoformans capsular polysaccharide
22. Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody
23. A human IgM monoclonal antibody prolongs survival of mice with lethal cryptococcosis
24. Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide
25. Protective murine monoclonal antibodies to Cryptococcus neoformans
26. Antibody immunity and invasive fungal infections
27. Antibody-mediated effects against Cryptococcus neoformans: Evidence for interdependency and collaboration between humoral and cellular immunity
28. Antibody mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection
29. Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies
30. Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice
31. Characterization of a murine monoclonal antibody to Cryptocococcus neoformans polysaccharide that is a candidate for human therapeutic studies
32. Return to the past: The case for antibody-based therapies in infectious diseases
33. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B
34. Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole activity
35. Combination of 5-flucytosine and capsule binding monoclonal antibody in therapy of murine Cryptococcus neoformans infections and in vitro
36. The fine structure of cerebral fluid accumulation. VII. Reactions of astrocytes to cryptococcal polysaccharide implantation
37. Elevated cerebrospinal fluid pressures in patients with cryptococcal meningitis and acquired immunodeficiency syndrome
38. Effect of immune mechanisms on the pharmacokinetics and organ distribution of cryptococcal polysaccharide
39. Cryptococcus neoformans meningitis in the rat
40. The results of the serum treatment in thirteen hundred cases of epidemic meningitis
41. Induction of human immunodeficiency virus type 1 expression in monocytic cells by Cryptococcus neoformans and Candida albicans
42. Enhancement of HIV-1 infection by the capsular polysaccharide of Cryptococcus neoformans
43. HIV-1 infectivity is increased in vitro by the presence of the capsular polysaccharide of Cryptococcus neoformans and Haemophilus influenzae
44. Pharmacokinetics and biodistribution of a monoclonal antibody to Cryptococcus neoformans capsular polysaccharide antigen in a rat model of cryptococcal meningitis: Implications for passive immunotherapy
45. Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody
46. Acute lethal toxicity following passive immunization for treatment of murine cryptococcosis
47. Antibody mediated toxicity in Cryptococcus neoformans infection: Mechanism and relationship to antibody isotype
48. Mechanism for the isotype dependence of antibody-mediated toxicity in Cryptococcus neoformans infected mice
49. Role of granulocytes in enhanced host resistance to Candida albicans induced by recombinant interleukin-1
50. Growth inhibition of Candida albicans by human polymorphonuclear neutrophils: Activation by interferon-γ and tumor necrosis factor
51. Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon
52. Recombinant and natural gamma-interferon activation of macrophages in vitro: Different dosage requirements for induction of killing activity against phagocytizable and nonphagocytizable fungi
53. Recombinant interferon-γ enhances resistance to acute disseminated Candida albicans infection in mice
54. Characteristics of invasive candidiasis in gamma interferon- and interleukin-4-deficient mice: Role of macrophages in host defense against Candida albicans
55. The role of recombinant murine IL-12 and IFN-gamma in the pathogenesis of a murine systemic Candida albicans infection
56. Interferon-γ protects endothelial cells from damage by Candida albicans
57. Individual differences in tumour necrosis factor and interleukin-1 production induced by viable and heat-killed Candida albicans
58. Disparate effects of interferon-γ and tumor necrosis factor-α on early neutrophil respiratory burst and fungicidal responses to Candida albicans hyphae in vitro
59. Pharmacological inhibitors of tumor necrosis factor production exert differential effects in lethal endotoxemia and in infection with live microorganisms in mice
60. Increased susceptibility of TNFαLTα double knockout mice to systemic candidiasis through impaired recruitment of neutrophils and phagocytosis of Candida albicans
61. TNF receptors in murine Candida albicans infection. Evidence for an important role of TNF receptor p55 in antifungal defense
62. CD40-CD40L interactions are necessary for host defense against disseminated candidiasis
63. Fas-FasL interactions modulate host defense against systemic Candida albicans infection
64. TNAα regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation
65. Cytokine treatment in central nervous system infection: Efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis
66. IL-12 is both required and prognostic in vivo for T helper type 1 differentiation in murine candidiasis
67. IL12 in Candida albicans infections
68. Neutrophil production of IL-12 and IL-10 in candidiasis and efficacy of IL-12 therapy in neutropenic mice
69. Enhanced killing of Candida albicans by murine macrophages treated with macrophage colony-stimulating factor: Evidence for augmented expression of mannose receptors
70. Macrophage colony-stimulating factor induction of enhanced macrophage anticryptococcal activity: Synergy with fluconazole for killing
71. Activation of human peripheral blood mononuclear cells by interleukin-2 and granulocyte-macrophage colony-stimulating factor to inhibit Cryptococcus neoformans
72. Granulocyte colony-stimulating factor potentiates anti-Candida albicans growth inhibitory activity of polymorphonuclear cells
73. Effects of granulocyte colony-stimulating factor and interferon-γ on antifungal activity of human polymorphonuclear neutrophils against pseudohyphae of different medically important Candida species
74. Granulocyte colony-stimulating factor administered in vivo augments neutrophil-mediated activity against opportunistic fungal pathogens
75. Granulocyte-colony stimulating factor facilitates the restoration of resistance to opportunistic fungi in leukopenic mice
76. Recombinant murine granulocyte colony stimulating factor protects against acute disseminated Candida albicans infection in non-neutropenic mice
77. Modulation of neutrophil function in host defense against disseminated Candida albicans infection in mice
78. Synergistic efficacy of recombinant human granulocyte colony-stimulating factor and amphotericin B against disseminated candidosis in non neutropenic mice
79. Antifungal combination therapy with granulocyte colony-stimulating factor and fluconazole in experimental disseminated candidiasis
80. Macrophage colony-stimulating factor in murine candidiasisserum and tissue levels during infection and protective effect of exogenous administration
81. Antifungal activity of recombinant human macrophage colony-stimulating factor in models of acute and chronic candidiasis in the rat
82. The deleterious effect of macrophage colony-stimulating factor (CSF-1) on the pathology of experimental candidiasis in mice
83. A double-blind, randomized, placebo-controlled Phase II study of filgrastim (recombinant granulocyte colony-stimulating factor) in combination with fluconazole for treatment of invasive candidiasis and candidemia in nonneutropenic patients
84. Use of amphotericin B with azole antifungal drugs: What are we doing?
85. Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B
86. Combination therapy with amphotericin B and fluconazole against invasive candidiasis in neutropenic-mouse and infective-endocarditis rabbit models
87. Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans
88. Interaction between fluconazole and amphotericin B in mice with systemic infection due to fluconazole-susceptible or -resistant strains of Candida albicans
89. Antagonistic interactions between azoles and amphotericin B with yeasts depend on azole lipophilia for special test conditions in vitro
90. Interactions of itraconazole with amphotericin B in the treatment of murine invasive candidiasis
91. Antifungal combination therapy: Where we stand